Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-valent HPV therapeutic vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Auro Vaccines is developing a 7-valent therapeutic HPV vaccine utilizing a heterologous prime-boost strategy for the treatment of cervical and head and neck cancers caused by human papillomavirus (HPV). The vaccine regimen consists of a DNA vaccine prime (GeneVax™), which is co-administered with Interleukin-12 (IL-12) and delivered via electroporation to initiate cellular immunity. This is followed by a boost with a vesicular stomatitis virus (VSV)-based viral vector (VesiculoVax™) designed to amplify HPV-specific T-cell immune responses. The vaccine targets seven high-risk HPV types responsible for over 92% of HPV-related cervical and head and neck cancers. By inducing robust cell-mediated immune responses against tumor-associated viral antigens, the vaccine aims to generate effector T cells capable of attacking virally infected and malignant cells, potentially serving as an adjunct to surgical treatment.
- Other names
- GeneVax + VesiculoVax HPV vaccineAuro Vaccines HPV therapeutic vaccine7-valent HPV therapeutic vaccine
02
Targets
HPV16 E6 oncoprotein
Beyond the preview
Go deeper on 7-valent HPV therapeutic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7-valent HPV therapeutic vaccine.